Post-marketing bridging data are validating companion diagnostics used to identify eligible patients for pembrolizumab in dMMR/MSI-H solid tumors. Merck & Co. reported results in BMC Cancer showing two commercially available tests can reliably reproduce the mismatch repair/microsatellite instability status that underpinned the original tumor-agnostic approval.